Monoclonal antibodies, studies show efficacy against Delta variant

<!– –>

The Covid–19 led to the need to hospitalize a very large number of patients. The resources of the National Health System and it was necessary to resort to containment measures never implemented before. While waiting for mass vaccination to avoid severe symptomatic disease and access to hospital, home care is the way forward to avoid situations similar to those of previous waves. Therefore, careful monitoring of patients becomes a priority to apply the therapies available for the different stages of the disease. Precisely in this regard, in recent weeks the panorama of monoclonal antibodies, a therapeutic option which brings family doctors closer to hospital specialists and which is also at the center of the European debate. In fact, in the last few days Stella Kyriakides, European Commissioner for Health and Food Safety, announced that theEuropean Union is aiming to authorize five possible new therapies against Covid-19: four monoclonal antibodies and an immunosuppressive drug. The vaccines in fact continue, but the virus will not disappear and we need to have safe and effective drugs.